Innere Medizin (Heidelberg, Germany)最新文献_第7页

[Beta-blockers in patients with preserved or mildly reduced ejection fraction after myocardial infarction]. [β受体阻滞剂在心肌梗死后射血分数保留或轻度降低患者中的应用]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2025-03-11 DOI: 10.1007/s00108-025-01878-5

Welf-Axel Geller, Johann Bauersachs, Sirka Nitschmann

引用次数: 0

KI in der Versorgung. 供应中的人工智能。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 DOI: 10.1007/s00108-025-01903-7

引用次数: 0

[Pharmacotherapy of obesity in Germany]. [德国肥胖的药物治疗]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2025-04-25 DOI: 10.1007/s00108-025-01897-2

Matthias Blüher

{"title":"[Pharmacotherapy of obesity in Germany].","authors":"Matthias Blüher","doi":"10.1007/s00108-025-01897-2","DOIUrl":"10.1007/s00108-025-01897-2","url":null,"abstract":"Pharmacotherapy is part of a comprehensive guideline-conform treatment concept for people with obesity. The foundation of obesity treatment is initially a conservative multimodal basic treatment and consists of a low-energy diet, increased physical activity and behavioral changes. If the individual treatment goals are not achieved with this approach, medications can support the basic treatment. The concept is that drugs should not only achieve weight reduction and stabilization of the reduced body weight but also provide better long-term treatment for the chronic multisystem disease obesity. The incretin-based pharmacotherapy with liraglutide, semaglutide and tirzepatide, which have been introduced in recent years, have not only pronounced weight-reducing but also beneficial cardiometabolic effects. These include improvements in obesity-related comorbidities, such as type 2 diabetes, hypertension, fatty liver disease, obstructive sleep apnea, cardiovascular risk factors, chronic kidney disease and others. In contrast, incretin-based pharmacotherapy is typically associated with mild to moderate gastrointestinal side effects. With the marketing launch of setmelanotide, a medication became available for the treatment of rare monogenic forms of obesity. In addition, numerous incretin-based active agents and new substance classes are in advanced phases of clinical development. Due to their favorable efficacy and side effect profiles and also with respect to the positive cardiometabolic effects, the new drugs have the potential to significantly increase the importance of pharmacotherapy of obesity in Germany.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":"66 5","pages":"475-484"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A rare medical chameleon with fatal consequences]. [一种具有致命后果的罕见医学变色龙]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2024-11-25 DOI: 10.1007/s00108-024-01814-z

Adrian Wullweber, Kristin Calaminus, Torsten Beyna

引用次数: 0

[Nivolumab and ipilimumab in patients with microsatellite instability-high metastatic colorectal cancer]. [Nivolumab和ipilimumab在微卫星不稳定性-高转移性结直肠癌患者中的应用]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.1007/s00108-025-01876-7

Martha Kirstein, Sirka Nitschmann, Jens Marquardt

引用次数: 0

[Principles of obesity treatment: What has changed in the updated S3 guideline?] 肥胖治疗原则：更新后的S3指南有哪些变化？］

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2025-04-08 DOI: 10.1007/s00108-025-01900-w

Nathalie Rohmann, Tim Hollstein, Matthias Laudes

{"title":"[Principles of obesity treatment: What has changed in the updated S3 guideline?]","authors":"Nathalie Rohmann, Tim Hollstein, Matthias Laudes","doi":"10.1007/s00108-025-01900-w","DOIUrl":"10.1007/s00108-025-01900-w","url":null,"abstract":"A comprehensive update of the S3 guideline for the prevention and treatment of obesity was published in October 2024. In contrast to the former version, the literature search included not only data on weight reduction but also data on patient-reported outcomes and co-morbidity. The new recommendations for nutritional therapy, besides fat and carbohydrate reduction, now also include novel aspects like the Mediterranean diet and intermittent fasting. These will enable individualization and will avoid an unbalanced diet. Pharmacotherapy, especially incretin-based, is recommended in an adjuvant setting, especially since current clinical trials indicate beneficial effects on the heart, liver and kidney in addition to weight reduction. A novel chapter was included regarding eHealth strategies, since these are efficient as supportive measures for multidimensional treatment programs, including nutritional advice, behavioural coaching and exercise training. Finally, a novel aspect was incorporated: discrimination and stigmatization of subjects suffering from obesity. This is important not only for the general environment but also for the medical sector, including the handling of patients as well as the infrastructure of the medical institution (e.g. heavy-duty chairs). Hence, the novel guideline will guarantee high quality in the medical care of subjects suffering from obesity.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"453-460"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143813005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Bariatric metabolic surgery 2025]. [减肥代谢手术2025]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.1007/s00108-025-01901-9

Thomas P Hüttl, Peter Stauch

{"title":"[Bariatric metabolic surgery 2025].","authors":"Thomas P Hüttl, Peter Stauch","doi":"10.1007/s00108-025-01901-9","DOIUrl":"10.1007/s00108-025-01901-9","url":null,"abstract":"Surgical procedures form an integral part of the interdisciplinary treatment of morbid obesity and its associated complications. The objective goes beyond mere weight control (bariatric surgery) and includes controlling the entire metabolism. Bariatric/metabolic procedures have not only become the currently most effective form of treatment for diabetes mellitus type 2 (DMT2) particularly in obese patients, but it has also proven to be a key tool for many other obesity-related secondary diseases. In addition to the main modes of action, i.e., restriction and malabsorption, numerous other mechanisms are the subject of research, since the metabolic effects in particular occur in the early postoperative period and can also be demonstrated in non-obese individuals. Today, a variety of surgical procedures are available to help address patient-specific issues. Examples include sleeve gastrectomy, Roux-en‑Y gastric bypass, omega loop bypass, single anastomosis duodeno-ileal bypass (SADI) surgery, single anastomosis sleeve-ileal bypass (SASI) surgery, biliopancreatic diversion with duodenal switch (BPD-DS), gastric band, and purely endoscopic procedures such as intragastric balloon or endoscopic sleeve gastroplasty (ESG). Long-term, structured, and preferably multidisciplinary follow-up care is essential for a positive long-term outcome and should include: nutritional therapy, laboratory tests, adjustment of pharmacotherapy, encouragement to take part in cancer screening, as well as vigilance regarding neurological symptoms and critical treatment situations such as weight regain, recurrence of depression or addiction problems.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":"66 5","pages":"467-474"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Atraumatic splenic rupture in Legionella pneumonia]. [军团菌肺炎中的创伤性脾破裂]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2024-12-23 DOI: 10.1007/s00108-024-01829-6

Niklas Frömmel, Ibtissame El Baraka, Bastian Walz, Bernhard Hellmich

引用次数: 0

[Transcatheter edge-to-edge repair in mitral regurgitation : RESHAPE-HF2 and MATTERHORN]. [经导管边缘对边缘修复二尖瓣反流：shape - hf2和MATTERHORN]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2025-04-02 DOI: 10.1007/s00108-025-01877-6

Florian Genske, Christian Frerker, Sirka Nitschmann

引用次数: 0

[Incretins as the basis of obesity treatment]. [肠促胰岛素作为肥胖治疗的基础]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-05-01 Epub Date: 2025-04-10 DOI: 10.1007/s00108-025-01893-6

Ines Freibothe, Timo Dirk Müller

引用次数: 0